SBC Medical Group Holdings Incorporated (SBC) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (73% profit margin, 63% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
As of 2026-11-03, SBC Medical Group Holdings Incorporated (NASDAQ: SBC) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $5.28 (-7.29% 1D, market cap $542.5M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, SBC ranks #63 in composite RQD confidence.
Within the Health Care sector (Medical/Nursing Services), SBC carries a Roarable B (72/100 RQD), trailing P/E of 11.5x, gross margin of 73.3%, and ROIC of 63.1%. By comparison, STLN (Starling Oncology Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $665.5M) and SRTA (Strata Critical Medical Inc. (Class A)) posts a E grade (34/100 RQD, P/E 10.2x, ROIC -7.1%, cap $392.8M). Among the 5-stock peer group, SRTA leads on earnings multiple (10.2x) while SBC leads on capital efficiency (63.1% ROIC).
Per SBC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001930313), SBC Medical Group Holdings Incorporated generated $173.6M in revenue (-15.5% YoY), $51.0M in net income, and $23.3M in free cash flow against $380.4M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (73% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 13.4% FCF Margin ($23.3M FCF) & 73.3% Gross Margin
SEC Form 4 / 13F Thermometer: 80% Net Buy • Cannibal Buyback (-2.36% YoY Shares)
Put hedging (50% put share) caps near-term gamma upside (-8 pts vs max)
Even with a 72/100 (B) score, SBC faces multiple-compression risk if 11.5x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Broader market pullbacks can still drag down strong stocks in the short run.
Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) — any gross margin slip below 70.8% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($4.92) or 200D SMA ($3.92) invalidates the momentum regime and cuts Target Base ($5.61) toward Bear Floor ($4.33).
SBC Medical Group Holdings Incorporated (SBC) dropped -7.29% to $5.28, trading at 83% of its 52-week range ($2.78 – $5.79). High-quality cash engine (73% profit margin, 63% return on capital) with steady institutional support.
Companies to co-develop AI features, starting with physician documentation support, to enhance medicalforce and SBC Medical’s in-house systems and drive per-clinic productivity and profitabilitySBC Medical Group
2026-10-27. The following slide deck was published by SBC Medical Group Holdings Incorporated in conjunction with this event.
IRVINE, Calif., October 22, 2026--SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ("The Company" or "SBC Medical"), a Medical Services Organization (MSO) providing management support across a wide range of healthca
SBC Medical Group Holdings Incorporated (NASDAQ:SBC) ("The Company" or "SBC Medical"), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today
Yuya Yoshida, Director, CFO and COO, to Present at the Forum in Hong Kong on October 26 and Hold One-on-One Investor Meetings on October 27; Non-Deal Roadshow to Follow on October 28IRVINE, Calif., Oct. 12, 2026 (GLOBE N
IRVINE, Calif., November 02, 2026--SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ("The Company" or "SBC Medical"), a Medical Services Organization (MSO) providing management support across a wide range of healthc
IRVINE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide
SBC Medical Group (NASDAQ:SBC) said its growth re-accelerated in the second quarter of 2026 following structural reforms undertaken in 2025, with profit growth exceeding revenue growth as the company expanded management
Adjusted EBITDA surges 32% to $20 million as clinic network expands to 287 locations and global initiatives gain momentum.
Net income surged 335% as structural reforms boosted margins and clinic expansion.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -15.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SBC today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SBC. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, SBC Medical Group Holdings Incorporated (SBC) ranks #63 by composite RQD confidence (72/100, grade B) and #428 by equity capitalization ($542.5M). Within this direct 5-issuer industry benchmark cohort, SRTA leads on earnings valuation at 10.2x trailing P/E, while SBC leads on capital efficiency and profitability with 63.1% ROIC and 73.3% gross margin. SBC currently leads its immediate peer cohort in composite quantitative strength at 72/100 (B).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SBC
ACTIVE
SBC Medical Group Holdings Incorporated | B | 72/100 | 11.5x | 73.3% | 63.1% | -7.29% | $542.5M | Benchmark Subject |
| STLN Starling Oncology Inc. | D- | 38/100 | — | — | -35.0% | -1.80% | $665.5M | /stln-vs-sbc → |
| SRTA Strata Critical Medical Inc. (Class A) | E | 34/100 | 10.2x | 20.9% | -7.1% | -6.53% | $392.8M | /srta-vs-sbc → |
| AHCO AdaptHealth Corp. | E | 33/100 | — | 18.8% | 2.2% | -2.02% | $792.2M | /ahco-vs-sbc → |
| AUNA Auna SA (Class A) | D | 45/100 | — | — | — | -6.04% | $333.8M | /auna-vs-sbc → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), SBC Medical Group Holdings Incorporated (SBC) reported GAAP revenue of $173.6M (-15.5% vs. FY2024 revenue of $205.4M , and -10.3% cumulative change since FY2023) , GAAP net income of $51.0M, operating cash flow of $24.7M, and free cash flow of $23.3M (+29.1% YoY). On the balance sheet, SBC closed FY2025 with $380.4M in total assets against $0 in total debt (Altman Z-Score: 5.46, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $173.6M | $51.0M | $24.7M | $23.3M | $380.4M | — |
| FY2024 (FY) | 2024-12-31 | $205.4M | $46.6M | $20.6M | $18.0M | $266.1M | — |
| FY2023 (FY) | 2023-12-31 | $193.5M | $39.4M | $50.7M | $50.7M | — | — |
As of 2026-11-03, SBC Medical Group Holdings Incorporated (NASDAQ: SBC) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $5.28 (-7.29% 1D, market cap $542.5M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, SBC ranks #63 in composite RQD confidence.
Within the Health Care sector (Medical/Nursing Services), SBC carries a Roarable B (72/100 RQD), trailing P/E of 11.5x, gross margin of 73.3%, and ROIC of 63.1%. By comparison, STLN (Starling Oncology Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $665.5M) and SRTA (Strata Critical Medical Inc. (Class A)) posts a E grade (34/100 RQD, P/E 10.2x, ROIC -7.1%, cap $392.8M). Among the 5-stock peer group, SRTA leads on earnings multiple (10.2x) while SBC leads on capital efficiency (63.1% ROIC).
Per SBC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001930313), SBC Medical Group Holdings Incorporated generated $173.6M in revenue (-15.5% YoY), $51.0M in net income, and $23.3M in free cash flow against $380.4M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (73% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
SBC last traded at $5.28 (-7.29% on volume of 155,303 shares), positioning the stock +7.32% above its 50-day simple moving average ($4.92) and +34.69% above its 200-day simple moving average ($3.92). Across its 52-week range of $2.78 to $5.79, SBC sits at the 83.1% percentile with a 14-day RSI of 50.7 (NEUTRAL RANGE) and an implied next-earnings move of ±11.0% ($4.70 to $5.86).
Why SBC Stock dropped -7.29% Today — RQD Quant Desk Flash. High-quality cash engine (73% profit margin, 63% return on capital) with steady institutional support.
Per the Roarable RQD rating, SBC scores 75 out of 100, grade B, labeled "Roarable Buy — Good Risk/Reward." The five pillars are:
Investor implications: Upside drivers in the data are high return on capital and a valuation that screens low on earnings (P/E TTM 11.5, Forward P/E 10.7, EV/EBITDA 6.1). The valuation tradeoff is that trailing EPS of 0.5 and a 52-week range of $2.78 to $5.79 mean the price has already moved substantially relative to its range. The shares trade near the top of that range at $5.69. The rating is a quantitative summary of the listed pillars and does not constitute personalized advice.
Per the Profile section, SBC Medical Group Holdings Incorporated is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Nursing Services industry. Per the Profile section, its market capitalization is $0.6B. Per the Market Data section, its gross margin is 73.3%, operating margin 38.9%, and net margin 29.4%. Not available in source data for products, customers, or the specific revenue model.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $173.6M | $67.5M | $51.0M | N/A | $23.3M | $163.8M | N/A |
| FY 2024 | $205.4M | $70.3M | $46.6M | N/A | $18.0M | $125.0M | N/A |
| FY 2023 | $193.5M | $70.7M | $39.4M | N/A | $50.7M | N/A | N/A |
Per the SEC financials, revenue declined from $205.4M in FY 2024 to $173.6M in FY 2025, while net income rose from $46.6M to $51.0M and cash increased from $125.0M to $163.8M. Operating margin is 38.9% and ROIC is 63.1% per the Market Data section. Altman Z-Score is 5.46 and Piotroski F-Score is 6/9 per the Roarable RQD rating, with Debt/Equity at 0.5. Not available in source data for the debt balance itself.
Real-time company headlines, analyst actions, and sector developments for SBC Medical Group Holdings Incorporated (SBC) • Click "Debate This Headline" to argue it in the Roar Pit below
Companies to co-develop AI features, starting with physician documentation support, to enhance medicalforce and SBC Medical’s in-house systems and drive per-clinic productivity and profitabilitySBC Medical Group
2026-10-27. The following slide deck was published by SBC Medical Group Holdings Incorporated in conjunction with this event.
IRVINE, Calif., October 22, 2026--SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ("The Company" or "SBC Medical"), a Medical Services Organization (MSO) providing management support across a wide range of healthca
SBC Medical Group Holdings Incorporated (NASDAQ:SBC) ("The Company" or "SBC Medical"), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today
Yuya Yoshida, Director, CFO and COO, to Present at the Forum in Hong Kong on October 26 and Hold One-on-One Investor Meetings on October 27; Non-Deal Roadshow to Follow on October 28IRVINE, Calif., Oct. 12, 2026 (GLOBE N
IRVINE, Calif., November 02, 2026--SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ("The Company" or "SBC Medical"), a Medical Services Organization (MSO) providing management support across a wide range of healthc
IRVINE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide
SBC Medical Group (NASDAQ:SBC) said its growth re-accelerated in the second quarter of 2026 following structural reforms undertaken in 2025, with profit growth exceeding revenue growth as the company expanded management
Welcome to the SBC (SBC Medical Group Holdings Incorporated) Roar Pit. Current RQD Composite is 75/100 (Roarable Buy — Good Risk/Reward) in Medical/Nursing Services. Bulls point to capital efficiency (63.1% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on SBC, but look at what you are paying: 11.5x trailing P/E with 73.3% gross margins. Unless SBC Medical Group Holdings Incorporated expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on SBC, the market is fixating on short-term headline noise in Medical/Nursing Services and ignoring the balance sheet and cash flow trajectory. At $5.69 (52-wk range $2.78 - $5.79), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).